Literature DB >> 7730604

Peptide and protein antigens require distinct antigen-presenting cell subsets for the priming of CD4+ T cells.

S Constant1, D Sant'Angelo, T Pasqualini, T Taylor, D Levin, R Flavell, K Bottomly.   

Abstract

Priming of naive CD4+ T cells to Ag requires an antigen-presenting cell (APC) that can take up the Ag and present peptide bound to MHC class II molecules. We have used both in vivo and in vitro approaches to demonstrate that the APC used to prime naive CD4+ T cells depends on the initial form in which an Ag is administered. Although Ag delivered as a peptide was presented most efficiently to CD4+ T cells by DC, these APC were poor at priming to a protein form of the same Ag. In contrast, the presence of B cells was a requisite for priming to protein Ag.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7730604

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  A viral protein that selectively downregulates ICAM-1 and B7-2 and modulates T cell costimulation.

Authors:  L Coscoy; D Ganem
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

2.  Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro.

Authors:  C J Kim; T Prevette; J Cormier; W Overwijk; M Roden; N P Restifo; S A Rosenberg; F M Marincola
Journal:  J Immunother       Date:  1997-07       Impact factor: 4.456

3.  B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity.

Authors:  Martin S Weber; Thomas Prod'homme; Juan C Patarroyo; Nicolas Molnarfi; Tara Karnezis; Klaus Lehmann-Horn; Dimitry M Danilenko; Jeffrey Eastham-Anderson; Anthony J Slavin; Christopher Linington; Claude C A Bernard; Flavius Martin; Scott S Zamvil
Journal:  Ann Neurol       Date:  2010-09       Impact factor: 10.422

4.  Epicutaneous immunization induces alphabeta T-cell receptor CD4 CD8 double-positive non-specific suppressor T cells that inhibit contact sensitivity via transforming growth factor-beta.

Authors:  Marian Szczepanik; Krzysztof Bryniarski; Monika Tutaj; Maria Ptak; Joanna Skrzeczynska; Philip W Askenase; Wlodzimierz Ptak
Journal:  Immunology       Date:  2005-05       Impact factor: 7.397

5.  Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges.

Authors:  Klaus Lehmann-Horn; Helena C Kronsbein; Martin S Weber
Journal:  Ther Adv Neurol Disord       Date:  2013-05       Impact factor: 6.570

6.  Concerted antigen presentation by dendritic cells and B cells is necessary for optimal CD4 T-cell immunity in vivo.

Authors:  Petra Kleindienst; Thomas Brocker
Journal:  Immunology       Date:  2005-08       Impact factor: 7.397

7.  Importance of B cells, but not specific antibodies, in primary and secondary protective immunity to the intracellular bacterium Francisella tularensis live vaccine strain.

Authors:  K L Elkins; C M Bosio; T R Rhinehart-Jones
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

Review 8.  Specific immunotherapy of cancer in elderly patients.

Authors:  S Matzku; M Zöller
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 9.  B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence.

Authors:  Silke Kinzel; Martin S Weber
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

10.  CD20+ T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer.

Authors:  Marco de Bruyn; Valerie R Wiersma; Maartje C A Wouters; Douwe F Samplonius; Harry G Klip; Wijnand Helfrich; Hans W Nijman; Paul Eggleton; Edwin Bremer
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.